Lyell Immunopharma Inc (LYEL)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current LYEL market cap is 152.12M. The company's latest EPS is USD -0.8403 and P/E is -0.65.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 317k | 654k | 1.09M | 989k | 764k |
| Operating Income | -59.04M | -59.51M | -55.58M | -51.53M | -50.51M |
| Net Income | -50.85M | -52.93M | -60.67M | -45.81M | -44.58M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 657k | 17.19M | 12.97M | 89.44M | 2.92M |
| Operating Income | -102.09M | -211.94M | -214.78M | -187.06M | -247.01M |
| Net Income | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 794.99M | 750.03M | 694.22M | 654.14M | 619.22M |
| Total Liabilities | 97.42M | 95.08M | 91.06M | 87.64M | 88.52M |
| Total Equity | 697.57M | 654.95M | 603.16M | 566.5M | 530.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 555.63M | 908.28M | 1.13B | 937.56M | 750.03M |
| Total Liabilities | 147.58M | 189.84M | 197.62M | 104.31M | 95.08M |
| Total Equity | -111.11M | -292.53M | 929.79M | 833.25M | 654.95M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -123.06M | -163.69M | -42.02M | -80.11M | -115.15M |
| Investing | 284.74M | 184.05M | 21.99M | 67M | 68.92M |
| Financing | 984k | 1.74M | 27k | 889k | 889k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 39.47M | -160.87M | -126.25M | -169.56M | -163.69M |
| Investing | -422.43M | -273.52M | -121.57M | -11.54M | 184.05M |
| Financing | 351.16M | 476.79M | 401.24M | 10.64M | 1.74M |
| Market Cap | 152.12M |
| Price to Earnings Ratio | -0.65 |
| Price to Sales Ratio | 52.38 |
| Price to Cash Ratio | 1.05 |
| Price to Book Ratio | 0.23 |
| Dividend Yield | - |
| Shares Outstanding | 279.22M |
| Average Volume (1 week) | 1.71M |
| Average Volume (1 Month) | 1.09M |
| 52 Week Change | -70.07% |
| 52 Week High | 3.2556 |
| 52 Week Low | 0.5448 |
| Spread (Intraday) | 0.05 (8.11%) |
| Company Name | Lyell Immunopharma Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://lyell.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
